This news article has expired. Below you will find a short description about the news article and comments that were left by CancerCompass users.
Bayer today announced results from a Phase II trial of regorafenib (BAY 73-4506), a potent oral multi- kinase inhibitor, which demonstrated that treatment with regorafenib resulted in a 31 percent partial response rate and 50 percent stabilization rate in patients with metastatic renal cell carcinoma (RCC).
We care about your feedback. Let us know how we can improve your CancerCompass experience.